Vani Commercials (538918)
Asset PlayScore breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹10.71 |
| Market Cap | ₹12.57 Cr |
| P/E Ratio | 14.24 |
| ROCE | 2.33% |
| ROE | 5.23% |
| Dividend Yield | 0% |
| Profit Growth | 53.33% |
| Debt/Equity | — |
| Sales Growth | 24.39% |
| 52-Week Range | ₹6.71 — ₹13.99 |
| Sector | Finance |
| Book Value | ₹11.8 |
Strengths
- Trades below book value: P/B 0.91 against book value of ₹11.80.
- Recent sales growth of 24.39% and profit growth of 53.33% show momentum.
- Piotroski F-Score of 7/9 indicates reasonably sound financial health.
- PEG of 0.37 suggests valuation appears inexpensive if growth sustains.
Concerns
- Latest quarter net profit is ₹0 crore (rounded) on ₹1 crore sales, showing extremely small and lumpy earnings.
- ROE of 5.23% and ROCE of 2.33% reflect weak capital deployment.
- No dividend, no promoter holding data, and no debt/equity disclosure reduce transparency.
- No identifiable moat; tiny NBFC in a competitive financial services space.
AI Analysis
At ₹10.71, Mr. Market is offering this NBFC at 91 paise for every rupee of book value. Book value is ₹11.80. That is the only compelling part. Vani Commercials is a micro-lender with a market cap of just ₹13 crore and quarterly sales of ₹1 crore. This is not a wonderful business; it is a tiny financial intermediary with no apparent moat. Return on equity is 5.23% and return on capital employed is 2.33%. Those are modest numbers, and as Graham would say, growth is only meaningful when achieved on a substantial base. The 53.33% profit growth and 24.39% sales growth are eye-catching, but the latest quarter net profit is ₹0 crore after rounding. That tells me earnings are lumpy and too small to value with confidence. The P/E of 14.24 and PEG of 0.37 look reasonable only if you believe the recent profit growth is durable. I do not have evidence of that. On the positive side, the Piotroski F-Score of 7 suggests reasonable financial health, and the balance sheet is not obviously strained, though debt/equity is not disclosed. There is no dividend, no promoter holding data, and no meaningful track record of high returns. This is not a compounder. It may be an asset play for a patient investor; the price is below book, but cheapness alone is never enough. I would need to see consistent profitability and better capital allocation before calling it a bargain. As Buffett says, it is far better to buy a wonderful business at a fair price than a fair business at a wonderful price. This is a fair business at a slight discount to book, and that is a very different proposition.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer